Follow The Filings

IMDX Insight Molecular Diagnostics

Insight Molecular Diagnostics earnings company data as of 4:48 AM ET 10/23

Limited consensus data for this ticker (thin coverage or data-plan limits). Dates may be company-announced rather than sell-side consensus. Calendar and recent prints remain the primary lens when available.

Scheduled

1 period, newest first, nothing reported yet. Each row shows EPS above revenue.

Period Date Metric Estimate Actual Result
FY2026 Q3 9 Nov EPS — — —
Rev — — —

Insider trades

Open-market buys and sales by IMDX's executives, directors and 10% owners in the last 12 months, from their Form 4s

All IMDX insider trades
  • $5.7M bought by 1 insider
  • None no sales outside a trading plan
  • None no planned (10b5-1) sales
  1. Broadwood Partners, L.P. 10% owner, +2 joint filers
    Buy
    $2M 570,184 shares at $3.56
    Traded Apr 23–27 Filed Apr 27
  2. Broadwood Partners, L.P. 10% owner, +2 joint filers
    Buy
    $653K 182,861 shares at $3.57
    Traded Apr 16–20 Filed Apr 20
  3. Broadwood Partners, L.P. 10% owner, +2 joint filers
    Buy
    $3M 521,739 shares at $5.75
    Traded Feb 10 Filed Feb 12

Also filed in the last 12 months, not counted as buying or selling: 7 share withholdings for taxes, 4 option exercises, and 3 stock grants.

SEC filings

Recent issuer filings from EDGAR, 23 shown.

Filed Form Detail Links
8-K 1.01,9.01
8-K 2.02,7.01,8.01,9.01
10-Q
8-K 5.02,5.07,9.01
8-K/A 8.01
8-K 2.02,9.01
10-Q
DEF 14A
8-K 8.01,9.01
DEFA14A
SCHEDULE 13D/A —
8-K 2.02,9.01
10-K
8-K 1.01,9.01
SCHEDULE 13D/A —
8-K 1.01,8.01,9.01
8-K 7.01,9.01
424B5
8-K 2.02,9.01
10-Q
8-K 5.02,9.01
8-K 5.02
10-Q

Estimates are consensus figures; SEC filings remain the official record. Not investment advice.